Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (SOPH) is a leader in AI-powered genomic analysis, enabling data-driven healthcare through its cloud-native SOPHiA DDM™ Platform. This page aggregates official company news and press releases, providing stakeholders with timely updates on advancements in precision medicine.
Access curated information on financial results, strategic partnerships, and technology innovations that shape the future of clinical diagnostics. Track developments in oncology solutions, regulatory milestones, and research collaborations across their global network of 1,000+ healthcare institutions.
Our repository includes updates on:
- FDA-cleared genomic profiling tools
- AI-driven diagnostic platform enhancements
- Cross-industry research initiatives in rare diseases
- Operational expansions and executive appointments
Bookmark this page for streamlined access to verified SOPHiA GENETICS updates, combining Swiss precision with cutting-edge analytics to transform patient care worldwide.
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) collaborates with Exactis Innovation, a non-profit network of hospital partners across Canada, to fuel cancer research and data-driven decision-making through the SOPHiA DDM™ platform. The collaboration aims to improve cancer survivorship in Canada by leveraging real-world data insights from multimodal datasets. The partnership will also enable Exactis to implement leading cancer testing solutions for its patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) partners with Hôpital Saint-Louis in Paris to implement the SOPHiA DDM™ Platform for research on Myeloid Disorders, aiming to provide data-driven care to patients with MPNs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (NASDAQ: SOPH) CEO Jurgi Camblong, PhD., to present at J.P. Morgan 2024 Healthcare Conference on January 11, 2024, in San Francisco.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) expands its suite of solutions under SOPHiA DDM™ for Liquid Biopsy, offering MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions to advance oncology research and tumor mutation profiling. Liquid biopsy testing provides an alternative to solid tumor testing by isolating cell-free DNA from blood plasma, allowing for faster, less invasive clinical decisions and simplified monitoring. The company's proprietary unique molecular identifier technology (CUMIN™) promises exceptional performance and reliable results in analyzing cell-free DNA samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announces expanded research partnership with CHU de Nîmes, a regional and university hospital in France. CHU de Nîmes will utilize SOPHiA DDM™ Platform for pharmacogenomics research, aiming to personalize medication response based on genetic profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (SOPH) expands its relationship with Città della Salute e della Scienza di Torino, the largest health center in Italy, to further utilize the SOPHiA DDM™ Platform on Microsoft Azure for research on homologous recombination repair (HRR) biomarkers. The cloud-native software company aims to support the hospital's research in various cancer types and rare diseases, revolutionizing data-driven medicine capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
News
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), is now live on the SOPHiA DDM™ Platform to advance its research into rare disorders, particularly male fertility. IHG PAS will use SOPHiA DDM™ Whole Exome Solution (WES) for next-generation sequencing (NGS) to accelerate research of inherited diseases, including infertility. The platform provides overnight analysis of WES and a rich knowledge base to help identify variants of interest associated with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS announced that BioReference Health, LLC will implement its technology and add MSK-ACCESS liquid biopsy to its test suite, making it the first laboratory globally to adopt this technology. The offering will be commercially available for ordering by healthcare providers through BioReference and its specialty division, GenPath Oncology, in 2024. The new liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
Rhea-AI Summary
SOPHiA GENETICS SA (Nasdaq: SOPH) reported financial results for Q3 2023, with revenue of $16.3 million, a 40% YoY growth. Operating loss improved by 30% YoY, and cash burn decreased to $15.8 million. The company reaffirmed its full-year guidance, expecting revenue growth of at least 30% and operating losses below 2022 levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
Sophia Genetics Sa